Search research articles
Contact Us
Filters
Showing results (61-70 of 79) with videos related to
Page
of 8
Sort By:
Pain Medicine (Malden, Mass.)
|
March 25, 2017
Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone
Lynn Webster, Jack Henningfield, August R Buchhalter, et al.
Pain Medicine (Malden, Mass.)
|
November 30, 2011
6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study
Janet Yancey-Wrona, Brian Dallaire, Edward Bilsky, et al.
Pain
|
July 28, 2004
Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain
Lowell Reynolds, Richard Rauck, Lynn Webster, et al.
Clinical and Translational Science
|
October 28, 2021
Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agonist, in recreational polydrug users
Megan J Shram, Robert H Spencer, Jenny Qian, et al.
Pain
|
January 1, 2008
Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain
Lynn Webster, Jan Peter Jansen, John Peppin, et al.
Pain
|
December 20, 2015
A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain
Eugene R Viscusi, Lynn Webster, Michael Kuss, et al.
BMC Infectious Diseases
|
April 17, 2026
Burden of clinical syndromes associated with pneumococcal disease in Mexico: a retrospective analysis for 2019
Juan Urrego-Reyes, Patricia Cornejo-Juárez, Jessica Lynn Webster, et al.
Current Medical Research and Opinion
|
May 16, 2022
Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate
Megan J Shram, Beatrice Setnik, Lynn Webster, et al.
Advances in Therapy
|
November 6, 2010
An enhanced bunionectomy model as a potential tool for early decision-making in the development of new analgesics
Hao Wang, Cynthia Gargano, Suzanne Lukac, et al.
Biotechnology and Bioengineering
|
March 11, 2021
Accelerating and de-risking CMC development with transposon-derived manufacturing cell lines
Sowmya Rajendran, Sowmya Balasubramanian, Lynn Webster, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 79) with videos related to
Sort By:
Page
of 8
Pain Medicine (Malden, Mass.)
|
March 25, 2017
Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone
Lynn Webster, Jack Henningfield, August R Buchhalter, et al.
Pain Medicine (Malden, Mass.)
|
November 30, 2011
6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study
Janet Yancey-Wrona, Brian Dallaire, Edward Bilsky, et al.
Pain
|
July 28, 2004
Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain
Lowell Reynolds, Richard Rauck, Lynn Webster, et al.
Clinical and Translational Science
|
October 28, 2021
Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agonist, in recreational polydrug users
Megan J Shram, Robert H Spencer, Jenny Qian, et al.
Pain
|
January 1, 2008
Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain
Lynn Webster, Jan Peter Jansen, John Peppin, et al.
Pain
|
December 20, 2015
A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain
Eugene R Viscusi, Lynn Webster, Michael Kuss, et al.
BMC Infectious Diseases
|
April 17, 2026
Burden of clinical syndromes associated with pneumococcal disease in Mexico: a retrospective analysis for 2019
Juan Urrego-Reyes, Patricia Cornejo-Juárez, Jessica Lynn Webster, et al.
Current Medical Research and Opinion
|
May 16, 2022
Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate
Megan J Shram, Beatrice Setnik, Lynn Webster, et al.
Advances in Therapy
|
November 6, 2010
An enhanced bunionectomy model as a potential tool for early decision-making in the development of new analgesics
Hao Wang, Cynthia Gargano, Suzanne Lukac, et al.
Biotechnology and Bioengineering
|
March 11, 2021
Accelerating and de-risking CMC development with transposon-derived manufacturing cell lines
Sowmya Rajendran, Sowmya Balasubramanian, Lynn Webster, et al.
Page
of 8